… MPH, genitourinary medical oncologist at Dana-Farber Cancer Center in Boston, Massachusetts, … with metastatic hormone-sensitive prostate cancer (mHSPC), including clinically meaningful … treatments that effectively control cancer while being tolerable for …

… , MD, a research fellow at Dana-Farber Cancer Institute, provided clinical perspective on … ) in HER2-positive metastatic breast cancer following the readout of data …

… for Genitourinary Oncology at Dana-Farber Cancer Institute and is an … medical oncologist at the Dana-Farber Cancer Institute. I' … with metastatic kidney cancer, meaning cancer that had spread … foundational treatments for kidney cancer patients. The key …

… from Penn Medicine Abramson Cancer Center.1 Biomarker testing … Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School. … non-small cell lung cancer (NeoADAURA). Updated May 23 … non-small cell lung cancer. Updated April 22, 2025 …

… , including scientists from the Dana-Farber Cancer Institute at Harvard Medical School … this research, colleagues at the Dana-Farber Cancer Institute — collaborators with UT … inhibitor treatment. Molecular explanation for cancer-drug resistance “This is …

… had a genetic predisposition to cancer. "That's … around 10% of children develop cancer because they have a … a pediatric oncologist at the Dana-Farber Cancer Institute and Boston Children… , the chief of the cancer genetics clinic at Texas Children …

… ), matching each with cancer-free controls. After accounting … Dr Timothy Rebbeck of Dana-Farber Cancer Institute told CNN … yellow pigments, citing potential cancer, genetic and reproductive risks … may create a compounding cancer risk. Moderation, vigilance, …

… breast, prostate and ovarian cancer. Many patients with these … San Antonio), along with Dana-Farber Cancer Institute at Harvard Medical … PARP inhibitors in BRCA1-deficient cancer cells. “This seminal … for each patient’s cancer journey. Reference: Rogers CM …

… with HER2-positive metastatic breast cancer. Interim results from the DESTINY … division of breast oncology at Dana-Farber Cancer Institute, Associate Professor of Medicine … Moore, MD Cleveland Clinic Taussig Cancer Institute Disclosures: Moore reports no …

… Antonio) in collaboration with Dana-Farber Cancer Institute at Harvard Medical … cancercancer drug resistance mechanismscollaborative cancer research initiativesCST complex … for breast and ovarian cancer treatmentPARP inhibitor resistancetherapeutic challenges …